4.7 Review

Spectrum of Restrictive and Infiltrative Cardiomyopathies Part 1 of a 2-Part Series

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 71, 期 10, 页码 1130-1148

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.01.016

关键词

amyloidosis; heart failure; restrictive cardiomyopathy

资金

  1. National Institute on Aging [R21AG53512]
  2. Alnylam
  3. Pfizer
  4. Prothena
  5. NATIONAL INSTITUTE ON AGING [R21AG053512] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Restrictive cardiomyopathies are the least common form of heart muscle disease. They are characterized as infiltrative and noninfiltrative, storage diseases, and endomyocardial disorders. Genetic diseases commonly present during childhood or adolescence. However, a growing percentage of elderly patients with heart failure with preserved ejection fraction are being recognized as having forms of restrictive cardiomyopathy, particularly cardiac amyloidosis. Noninvasive evaluation has replaced endomyocardial biopsy in the diagnostic evaluation of most suspected etiologies. The detection of infiltrative cardiomyopathies, including lysosomal and glycogen storage disorders, iron overload, and amyloidosis (both light chain amyloidosis and transthyretin amyloidosis variants), as well as inflammatory diseases such as sarcoidosis has slowly led to improved outcomes via disease-specific therapies. (c) 2018 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据